The Business of AI in Healthcare: Keynote by Philip Low, CEO, NeuroVigil followed by high profile Panel

October 25, 2017 @ 5:30 pm – 8:30 pm
Knobbe Martens
12790 El Camino Real
San Diego, CA 92130
Anita Rusch
858-771-MIT1 (858-771-6481)

PROGRAM:  The business of Artificial Intelligence —  solving the grand challenges in Health Care

DESCRIPTION:   How can  (AI) be applied to bend the $ 3.2 trillion a year healthcare cost curve, yet allow life science companies to create capital efficient business models that attract investors?  Learn from the most prominent tech and life science leaders about challenges and opportunities with AI and Healthcare. 

There is little doubt that transformational change is coming (AI/Machine Learning), and tech companies ranging in size from small startups to corporate titans like IBM and GE are scrambling to gain a foothold in this emerging field. The sector represents a lucrative-but-daunting target for investors—complicated by regulatory issues, a healthcare system that separates the interests of patients, providers, and payers, and an investment timeline that can take 10 years or more to realize.

CureMatch is taking a direct-to-consumer approach, in which cancer patients pay CureMatch to recommend the top three combinations of chemotherapy drugs for each patient’s cancer. The recommendations, based on information in a patient’s own medical record, is intended to help cancer specialists choose a treatment regimen. CureMatch says it uses supercomputer processing to sort through millions of possible three-drug combinations, assessing each combination for factors like unwanted drug-drug interactions, and correlating genomic data to rank the best drug combinations for a specific patient.

KEYNOTE:  Philip Low, PhD, Founder, Chairman & C.E.O., NeuroVigil, Inc.

SPECIAL INTRODUCTION:  Eugene Izhikevich, Ph.D, Founder & CEO, Brain Corp.


  1. Stephane Richard,  Ph.D., President & COO, CureMatch
  2. Colin Lawlor, CEO, SleepScore Labs
  3. Kim Kamdar, Ph.D., Partner, Domain Associates
  4. Navid Alipour, Managing Partner, Analytics Ventures
  5. Joshua Windmiller, Ph.D., Co-Founder and CTO, BioLinq

MODERATOR:  Christopher Rowan, NewCap Partners; Managing Partner, Arscientia


Dr. Philip Steven Low made his first scientific discovery at Harvard Medical School, as a teenager. While inventing new brain monitoring techniques at the University of Chicago, he was referred to the Salk Institute by Francis Crick, Nobel Laureate of DNA fame, where he authored a 1 page PhD thesis on dynamic brain activity mapping, which led to his creation of NeuroVigil, the neurotechnology company responsible for iBrain, a portable brain activity monitor, with first and second round valuations two and two-and-a-half times Google’s and Facebook’s combined, respectively, as well as to the Cambridge Declaration on Consciousness, the first formal document by Neuroscientists recognizing consciousness in non-humans.

He was appointed to dual positions at the Stanford School of Medicine and the MIT Media Lab in his twenties. His partners include Roche and Novartis, his collaborators include Stephen Hawking and NASA, his advisors include Stephen Wolfram and Nobel Laureates Sydney Brenner and Roger Guillemin and his backers include IdeaLab’s Howard Morgan, Qualcomm’s Irwin Jacobs & Andrew Viterbi, DFJ’s Tim Draper and SpaceX’s and Tesla’s Elon Musk. He chaired the 1st Intl. Congress on Alzheimer’s & Advanced Neurotech as well as the Francis Crick Memorial Conference. He advises the White House, Congress, the US Armed Forces and the Israeli Government on Neurotech.

Dr. Low’s honors include the MIT TR-35 Top Young Innovator Award, the DFJ Venture Challenge and the Jacobs-Rady Pioneer Award for Global Innovation & Entrepreneurship. His inventions and discoveries have been profiled in scientific and popular media including Science, PNAS, CNN, TIME, Newsweek, Forbes, the Economist, the Washington Post which lists NeuroVigil as one of the “Top 10 Most Innovative Companies in Health Care”, The Scientist which singled out Dr. Low as “A Scientist to Watch” and the New York Times which has recognized iBrain as “an innovation that will change your tomorrow.”


5:30: Registration, Appetizers and Networking
6:30: Announcements

6:40: Keynote
7:45: Panel Discussion

8:30: Audience Q & A
8:45: Program Concludes, Networking, Coffee & Dessert

MITEF Members and MITEF Sponsors: FREE
Non-members: $65
MIT Alums:  $50
​​On-Site: $75

NOTE:  Online Registration ends at noon the day of the event.  After that time, you may register on-site for $75

PAYPAL is our payment processor and accepts ALL MAJOR Credit Cards.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.